The mechanisms of these serum changes in breast cancer need to be further investigated and might reflect compensatory mechanisms against developing microtumors and/or redistribution/sequestration of RANKL/OPG within different body compartments. The gene discussed is TNFRSF11B; the disease is breast carcinoma.